Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
- Authors
- Park, Inkeun; Lee, Jae-Lyun; Ahn, Jin-Hee; Lee, Dae-Ho; Lee, Kyoo-Hyung; You, Dalsan; Jeong, In Gab; Song, Cheryn; Hong, Bumsik; Hong, Jun Hyuk; Ahn, Hanjong
- Issue Date
- May-2015
- Publisher
- SPRINGER
- Keywords
- Renal cell carcinoma; mTORi; VEGFR-TKI; Metastasis; Rechallenge
- Citation
- CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.75, no.5, pp.1025 - 1035
- Journal Title
- CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Volume
- 75
- Number
- 5
- Start Page
- 1025
- End Page
- 1035
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10578
- DOI
- 10.1007/s00280-015-2725-8
- ISSN
- 0344-5704
- Abstract
- To assess the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for metastatic renal cell carcinoma (mRCC) patients and to identify predictive factors for increased progression-free survival (PFS) or overall survival (OS). The clinicopathological features, outcomes, and prognostic factors of mRCC patients who were treated with VEGFR-TKI after treatment failure using both VEGFR-TKIs and mTOR inhibitors (mTORi) were reviewed. A total of 29 eligible patients were included. Five (17 %) patients achieved partial response (PR) with a median response duration of 9.5 months (95 % CI 5.7-13.4 months), and additional 16 patients (55 %) achieved stable disease. With a median follow-up period of 19.2 months (95 % CI 18.9-19.6 months), the median PFS and OS were 3.0 months (95 % CI 1.1-4.9 months) and 4.9 months (95 % CI 2.9-6.8 months), respectively. In univariate analysis, the best response to first-line VEGFR-TKI (PR vs. non-PR, p < 0.001) and time to rechallenge (TTR, a parts per thousand currency sign12 months vs. between 12 and 24 months vs. > 24 months, p = 0.005) were identified as predictive factors for longer PFS on VEGFR-TKI rechallenge. In addition, an MSKCC risk group (intermediate- vs. poor-risk group, p = 0.027), better response at first-line VEGFR-TKI (PR vs. non-PR, p = 0.003), and TTR (a parts per thousand currency sign12 months vs. between 12 and 24 months vs. > 24 months, p = 0.026) were identified as prognostic factors for longer OS. VEGFR-TKI rechallenge may be a viable option for select metastatic RCC patients who fail both VEGFR-TKI and mTORi therapies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10578)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.